Related Experiment Video
Updated: Jan 17, 2026
08:32
CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications
Published on: August 9, 2022
4.3K
Real World Study on the Best CPX-351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation
Fabio Guolo1,2, Luana Fianchi3, Maria Paola Martelli4
1University of Genoa, Department of Internal Medicine (DiMI), Genoa, Italy.
American Journal of Hematology
|September 24, 2025
Summary
CPX-351 improves outcomes in secondary acute myeloid leukemia (s-AML). Allogeneic stem cell transplant (allo-HSCT) is beneficial, especially when performed early after achieving remission. Patients not undergoing transplant benefit from completing all CPX-351 cycles.
Area of Science:
- Hematology
- Oncology
- Clinical Trials
Background:
- Secondary acute myeloid leukemia (s-AML) has poorer outcomes compared to de novo AML.
- CPX-351 demonstrated superiority over conventional 3+7 chemotherapy in a registration trial for s-AML.
- Optimal treatment duration, timing of allogeneic stem cell transplantation (allo-HSCT), and CPX-351 activity in s-AML subgroups require further investigation.
Purpose of the Study:
- To retrospectively analyze the outcomes of s-AML patients treated with CPX-351.
- To evaluate the impact of treatment duration, timing of allo-HSCT, and specific patient subgroups on CPX-351 efficacy.
- To identify factors influencing overall survival (OS) in s-AML patients receiving CPX-351.
Main Methods:
- Retrospective analysis of 513 s-AML patients treated with CPX-351.
- Assessment of complete remission (CR) rates after induction and consolidation cycles.
- Evaluation of allo-HSCT utilization, consolidation cycle completion, and their association with OS.
Main Results:
- The CR rate was 58% after induction, increasing to 66% after cycle 2.
- 48.8% of patients received allo-HSCT, associated with significantly longer OS (not reached vs. 16.3 months).
- Patients with NPM1 mutations or ELN 2017 favorable risk had longer OS. Completing CPX-351 cycles benefited only non-transplanted patients.
Conclusions:
- CPX-351 is effective in s-AML, with CR rates improving after a second cycle.
- Early allo-HSCT upon achieving CR is recommended for eligible s-AML patients.
- Complete CPX-351 treatment courses benefit patients not proceeding to transplant, while early transplant is key for others.
